Advisory Advocates’s ResMed RMD Stock Holding History

Advisory Advocates’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,041	Closed	-$234K	–	198
2026 Q1	$234K	Buy	1,041 +137	+15%	+$34.1K	0.24%	139
2025 Q4	$218K	Buy	+904	New	+$231K	0.22%	145

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Advisory Advocates's RMD Position: Q2 2026 in Review

Advisory Advocates sold out of ResMed (RMD) in Q2 2026, closing a stake of 1,041 shares — an estimated $234K sold.

Advisory Advocates first reported a position in RMD in Q4 2025 and held it in 2 quarters. The position peaked at $234K in Q1 2026. 836 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Advisory Advocates reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
Advisory Advocates sold 1,041 ResMed shares in Q2 2026, an estimated $234K.
Advisory Advocates first reported a position in ResMed in Q4 2025 and held it in 2 quarters.
Advisory Advocates's ResMed position peaked at $234K in Q1 2026.
836 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Advisory Advocates's 13F filing for Q2 2026, filed 10 Aug 2026.